|
Wednesday, November 16, 2022
Print Current Session:
 |
|
|
Wednesday
SESSION 31:
ADVANCES IN MEDICAL TREATMENTS, NEW ANTI-ATHEROGENIC DRUGS, VALUE OF RIVAROXABAN AND PREVENTING MIs IN VASCULAR SURGERY PATIENTS
|
|
| SESSION 31 SCHEDULE | |
| 6:46 AM - 6:51 AM Power Point Presentation with Synched Audio |
New Information From The VOYAGER And COMPASS Trials With Rivaroxaban (Xarelto From Janssen And J&J) And Aspirin: How Does It Help In The Management Of Patients With Arterial And Venous Disease: With And Without Kidney Disease And With And Without Statins |
|
Presenter(s):Marianne Brodmann, MD Location: Grand Ballroom West, 3rd Floor |
|
| 6:52 AM - 6:57 AM | New Strategies On How To Avoid And Treat Perioperative Myocardial Infarctions (MIs) In Open Vascular Surgery Patients |
|
Presenter(s):Peter Henke, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 6:58 AM - 7:03 AM Power Point Presentation with Synched Audio |
Update On LDL-C Lowering During A Lifetime: How Low To Strive For With Intensive Drug Therapy: How Young To Start If High; How Old To Continue Statins |
|
Presenter(s):J. David Spence, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:04 AM - 7:09 AM | DEBATE: LDL-C Lowering And Statins For Prophylaxis Of Vascular Events Are Dangerous And Not Helpful: What Does The Latest Evidence Show |
|
Presenter(s):Sherif A.H. Sultan, MD, PhD, FRCS, EBQS-VASC, FACS Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:10 AM - 7:15 AM | DEBATE: Not So: Update On LDL-C Lowering With Statins And Other Drugs Stabilizes And Shrinks Plaques And Decreases Morbid Vascular Events: Stopping Statins Increases Patients’ Risk Of MI And Death |
|
Presenter(s):Ron Waksman, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:16 AM - 7:21 AM | Low Dose Rivaroxaban (Xarelto From Janssen And J&J) And Aspirin Improve Survival And Decrease Major Adverse Limb Events (MALE) After Endo And Open Treatments For PAD/CLTI: From The VOYAGER RCT: What Does The XATOA Prospective Registry Add |
|
Presenter(s):Sebastian E. Debus, MD, PhD / Marianne Brodmann, MD Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:22 AM - 7:27 AM Power Point Presentation with Synched Audio |
How Does The Morbidity And Pathology Of Adverse Events With Arteriosclerosis Depend On Thrombosis: This Explains The Benefits Of Rivaroxaban And Aspirin Seen In The VOYAGER And COMPASS Trials |
|
Presenter(s):Anthony J. Comerota, MD, FACS, FACC Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:28 AM - 7:33 AM | New Adjunctive Drugs (Plus Statins) To Lower LDL-Cholesterol (LDL-C) In Vascular Patients: Inclisiran, Bempedoic Acid And Ezetimbe: How Do They Work And When And How To Use Them: Level Of LDL-C To Strive For |
|
Presenter(s):Richard Bulbulia, MA, MD, FRCS Location: Grand Ballroom West, 3rd Floor |
|
| View Slides in PDF | |
| 7:34 AM - 7:42 AM | Panel Discussion |
| END OF SESSION 31 | |
| previous | next |